Pfizer Plans For Three Biosimilar Launches In Japan and US This Year
Trastuzumab, rituximab and bevacizumab are slated for launch later this year as Pfizer builds out its biosimilar oncology offering.
Trastuzumab, rituximab and bevacizumab are slated for launch later this year as Pfizer builds out its biosimilar oncology offering.